Halsey J - Search Results

1

Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.

Lum BL, Fisher GA, Brophy NA, Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI. Lum BL, et al. Among authors: halsey j. Cancer. 1993 Dec 1;72(11 Suppl):3502-14. doi: 10.1002/1097-0142(19931201)72:11+<3502::aid-cncr2820721618>3.0.co;2-n. Cancer. 1993. PMID: 7902206 Review.

2

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma.

Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, Holmlund JT, Dorr A, Sikic BI. Advani R, et al. Among authors: halsey j. Cancer. 2004 Jan 15;100(2):321-6. doi: 10.1002/cncr.11909. Cancer. 2004. PMID: 14716767 Free article. Clinical Trial.

3

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.

Yahanda AM, Alder KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI. Yahanda AM, et al. Among authors: halsey j. J Clin Oncol. 1992 Oct;10(10):1624-34. doi: 10.1200/JCO.1992.10.10.1624. J Clin Oncol. 1992. PMID: 1403040 Clinical Trial.

4

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI. Lum BL, et al. Among authors: halsey j. J Clin Oncol. 1992 Oct;10(10):1635-42. doi: 10.1200/JCO.1992.10.10.1635. J Clin Oncol. 1992. PMID: 1403041 Clinical Trial.

5

The use of probenecid as a chemoprotector against cisplatin nephrotoxicity.

Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, Sikic BI. Jacobs C, et al. Among authors: halsey j. Cancer. 1991 Mar 15;67(6):1518-24. doi: 10.1002/1097-0142(19910315)67:6<1518::aid-cncr2820670610>3.0.co;2-3. Cancer. 1991. PMID: 1848154 Clinical Trial.

6

Enhancement of the clinical activity of melphalan by the hypoxic cell sensitizer misonidazole.

Coleman CN, Carlson RW, Artim RA, Sampson WI, Lawrence HJ, Wong P, Halsey J, Kohler M, Gribble M, Sikic BI, et al. Coleman CN, et al. Among authors: halsey j. Cancer Res. 1988 Jun 15;48(12):3528-32. Cancer Res. 1988. PMID: 2836059 Clinical Trial.

7

Clinical reversal of multidrug resistance.

Sikic BI, Fisher GA, Lum BL, Brophy NA, Yahanda AM, Adler KM, Halsey J. Sikic BI, et al. Among authors: halsey j. Cancer Treat Res. 1994;73:149-65. doi: 10.1007/978-1-4615-2632-2_8. Cancer Treat Res. 1994. PMID: 7710904 Review. No abstract available.

8

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI. Bartlett NL, et al. Among authors: halsey j. J Clin Oncol. 1994 Apr;12(4):835-42. doi: 10.1200/JCO.1994.12.4.835. J Clin Oncol. 1994. PMID: 8151326 Clinical Trial.

9

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.

Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, Chen G. Sikic BI, et al. Among authors: halsey j. Cancer Chemother Pharmacol. 1997;40 Suppl:S13-9. doi: 10.1007/s002800051055. Cancer Chemother Pharmacol. 1997. PMID: 9272128 Review.

10

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.

Advani R, Fisher GA, Lum BL, Hausdorff J, Halsey J, Litchman M, Sikic BI. Advani R, et al. Among authors: halsey j. Clin Cancer Res. 2001 May;7(5):1221-9. Clin Cancer Res. 2001. PMID: 11350887 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

312 results

Search Page